These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 26483203)

  • 1. JX06 Selectively Inhibits Pyruvate Dehydrogenase Kinase PDK1 by a Covalent Cysteine Modification.
    Sun W; Xie Z; Liu Y; Zhao D; Wu Z; Zhang D; Lv H; Tang S; Jin N; Jiang H; Tan M; Ding J; Luo C; Li J; Huang M; Geng M
    Cancer Res; 2015 Nov; 75(22):4923-36. PubMed ID: 26483203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of the First Generation of Disulfide-Based Subtype-Selective and Potent Covalent Pyruvate Dehydrogenase Kinase 1 (PDK1) Inhibitors.
    Liu Y; Xie Z; Zhao D; Zhu J; Mao F; Tang S; Xu H; Luo C; Geng M; Huang M; Li J
    J Med Chem; 2017 Mar; 60(6):2227-2244. PubMed ID: 28230989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel PDK1 inhibitor, JX06, inhibits glycolysis and induces apoptosis in multiple myeloma cells.
    Kawano Y; Sasano T; Arima Y; Kushima S; Tsujita K; Matsuoka M; Hata H
    Biochem Biophys Res Commun; 2022 Jan; 587():153-159. PubMed ID: 34875534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Novel Pyruvate Dehydrogenase Kinase 1 (PDK1) Inhibitors by Kinase Activity-Based High-Throughput Screening for Anticancer Therapeutics.
    Zhang W; Hu X; Chakravarty H; Yang Z; Tam KY
    ACS Comb Sci; 2018 Nov; 20(11):660-671. PubMed ID: 30350563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Cancer Metabolism Plasticity with JX06 Nanoparticles via Inhibiting PDK1 Combined with Metformin for Endometrial Cancer Patients with Diabetes.
    Yang X; Cheng Y; Zhou J; Zhang L; Li X; Wang Z; Yin S; Zhai L; Huang T; Wu X; Shen B; Dong Y; Zhao L; Chi Y; Jia Y; Wang J; He Y; Dong X; Xiao H; Wang J
    Adv Sci (Weinh); 2022 Mar; 9(8):e2104472. PubMed ID: 35064767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenyl butyrate inhibits pyruvate dehydrogenase kinase 1 and contributes to its anti-cancer effect.
    Zhang W; Zhang SL; Hu X; Tam KY
    Eur J Pharm Sci; 2017 Dec; 110():93-100. PubMed ID: 28450154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of (R)-3,3,3-trifluoro-2-hydroxy-2-methylpropionamides as pyruvate dehydrogenase kinase 1 (PDK1) inhibitors to reduce the growth of cancer cells.
    Zhang SL; Zhang W; Yang Z; Hu X; Tam KY
    Eur J Pharm Sci; 2017 Dec; 110():87-92. PubMed ID: 28347773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of pyruvate dehydrogenase kinase 1 inhibitors with anti-osteosarcoma activity.
    Fang A; Luo H; Liu L; Fan H; Zhou Y; Yao Y; Zhang Y
    Bioorg Med Chem Lett; 2017 Dec; 27(24):5450-5453. PubMed ID: 29150396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dichloroacetophenones targeting at pyruvate dehydrogenase kinase 1 with improved selectivity and antiproliferative activity: Synthesis and structure-activity relationships.
    Zhang SL; Yang Z; Hu X; Tam KY
    Bioorg Med Chem Lett; 2018 Nov; 28(21):3441-3445. PubMed ID: 30266541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ilimaquinone Induces the Apoptotic Cell Death of Cancer Cells by Reducing Pyruvate Dehydrogenase Kinase 1 Activity.
    Kwak CH; Jin L; Han JH; Han CW; Kim E; Cho M; Chung TW; Bae SJ; Jang SB; Ha KT
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticancer effects of some novel dichloroacetophenones through the inhibition of pyruvate dehydrogenase kinase 1.
    Zhang SL; Yang Z; Hu X; Chakravarty H; Tam KY
    Eur J Pharm Sci; 2018 Oct; 123():43-55. PubMed ID: 30012506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The phosphoinositide-dependent protein kinase 1 inhibitor, UCN-01, induces fragmentation: possible role of metalloproteinases.
    Alcántara-Hernández R; Hernández-Méndez A; García-Sáinz JA
    Eur J Pharmacol; 2014 Oct; 740():88-96. PubMed ID: 25016091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective 3-phosphoinositide-dependent kinase 1 (PDK1) inhibitors: dissecting the function and pharmacology of PDK1.
    Medina JR
    J Med Chem; 2013 Apr; 56(7):2726-37. PubMed ID: 23448267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitors.
    Medina JR; Becker CJ; Blackledge CW; Duquenne C; Feng Y; Grant SW; Heerding D; Li WH; Miller WH; Romeril SP; Scherzer D; Shu A; Bobko MA; Chadderton AR; Dumble M; Gardiner CM; Gilbert S; Liu Q; Rabindran SK; Sudakin V; Xiang H; Brady PG; Campobasso N; Ward P; Axten JM
    J Med Chem; 2011 Mar; 54(6):1871-95. PubMed ID: 21341675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dicumarol inhibits PDK1 and targets multiple malignant behaviors of ovarian cancer cells.
    Zhang W; Su J; Xu H; Yu S; Liu Y; Zhang Y; Sun L; Yue Y; Zhou X
    PLoS One; 2017; 12(6):e0179672. PubMed ID: 28617852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substrate-selective inhibition of protein kinase PDK1 by small compounds that bind to the PIF-pocket allosteric docking site.
    Busschots K; Lopez-Garcia LA; Lammi C; Stroba A; Zeuzem S; Piiper A; Alzari PM; Neimanis S; Arencibia JM; Engel M; Schulze JO; Biondi RM
    Chem Biol; 2012 Sep; 19(9):1152-63. PubMed ID: 22999883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ciprofloxacin Therapy Results in Mitigation of ATP Loss after Irradiation Combined with Wound Trauma: Preservation of Pyruvate Dehydrogenase and Inhibition of Pyruvate Dehydrogenase Kinase 1.
    Swift JM; Smith JT; Kiang JG
    Radiat Res; 2015 Jun; 183(6):684-92. PubMed ID: 26010714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic and pharmacological inhibition of PDK1 in cancer cells: characterization of a selective allosteric kinase inhibitor.
    Nagashima K; Shumway SD; Sathyanarayanan S; Chen AH; Dolinski B; Xu Y; Keilhack H; Nguyen T; Wiznerowicz M; Li L; Lutterbach BA; Chi A; Paweletz C; Allison T; Yan Y; Munshi SK; Klippel A; Kraus M; Bobkova EV; Deshmukh S; Xu Z; Mueller U; Szewczak AA; Pan BS; Richon V; Pollock R; Blume-Jensen P; Northrup A; Andersen JN
    J Biol Chem; 2011 Feb; 286(8):6433-48. PubMed ID: 21118801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of an inactivating cysteine switch in protein kinase Cepsilon, a rational target for the design of protein kinase Cepsilon-inhibitory cancer therapeutics.
    Chu F; Koomen JM; Kobayashi R; O'Brian CA
    Cancer Res; 2005 Nov; 65(22):10478-85. PubMed ID: 16288040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. For a PDK1 inhibitor, the substrate matters.
    Knight ZA
    Biochem J; 2011 Jan; 433(2):e1-2. PubMed ID: 21175429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.